Last reviewed · How we verify
Flixotide pMDI 250 micrograms
Fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.
Fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Flixotide pMDI 250 micrograms |
|---|---|
| Sponsor | Mundipharma Research Limited |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone propionate exerts anti-inflammatory effects by activating intracellular glucocorticoid receptors, which suppress the production of inflammatory cytokines and mediators in airway tissues. This reduces mucus production, airway edema, and eosinophil infiltration, thereby improving airflow and reducing asthma symptoms. The pMDI (pressurized metered-dose inhaler) formulation delivers the drug directly to the lungs for local action with minimal systemic absorption.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oropharyngeal candidiasis
- Dysphonia
- Tremor
- Headache
- Palpitations
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flixotide pMDI 250 micrograms CI brief — competitive landscape report
- Flixotide pMDI 250 micrograms updates RSS · CI watch RSS
- Mundipharma Research Limited portfolio CI